Duta in Europa

[Rio]

Guardate su gsk.com...e abbiate un po' di pazienza

 

GlaxoSmithKline plc (GSK) today announces that it has received European approvals, for Avodart® (dutasteride), a new treatment for benign prostatic hyperplasia (BPH). Major European countries have approved an indication for the use of Avodart® in the treatment of moderate to severe symptoms of BPH and for the reduction in risk of acute urinary retention (AUR) and surgery, in patients with BPH. Following review under the Mutual Recognition Procedure (MRP), these approvals come 90 days after dutasteride was first approved by the Reference Member State Sweden; (in Sweden dutasteride has been approved with the trade name Avolve®). GSK plan to market Avodart® in all major European markets with launches in the first half of 2003.

 

Commenting on the approval, Professor Roger Kirby, Professor of Urology, St George's Hospital, London said: "Avodart provides BPH patients and their doctors with a new long-term treatment option. In clinical trials involving in excess of 4,300 patients with BPH over two years, Avodart provided long lasting symptom improvement and reduced the risk of AUR - the sudden complete inability to urinate - by 57 percent, and the need for BPH-related surgery by 48 percent."

 

Avodart is the first and only 5-alpha reductase inhibitor (5ARI) that inhibits both the type 1 and 2 isoenzymes of 5-alpha reductase, the enzyme responsible for converting testosterone to dihydrotestosterone (DHT) in the prostate and other tissues. DHT is the primary cause of prostate growth that has been proven to play a key role in the development and progression of BPH. Avodart decreases levels of DHT by 90 percent and this is maintained at two years.

 

BPH is a common benign growth in ageing men. It is this non-cancerous enlargement of the prostate gland that frequently causes lower urinary tract symptoms (LUTS). BPH is a progressive disease and if left untreated for a long duration, can in severe cases result in complications such as AUR and surgery requiring hospitalisation.

 

Overall, in clinical trials, the most commonly reported adverse events as reported in the approved Summary of Product Characteristics were impotence (6%), altered / decreased libido (3.7%), ejaculation disorder (1.8%), gynaecomastia (1.3%).

 

 

[zionio]

WOWOWOWOWOWOW era ora...

[kill a loop]

effetti collaterali: 6% impotenza??? o impotence in inglese significa un'altra cosa?

 

zat

[tristan]

kill......credo ke tu abbia capito benissimo................. .....

 

cciiaaoo

[plastiko]

un pò alta come percentuale :/ ..credo che come sempre sia reversibile però!

[gavin3]

sara' reversibile pero' sono convinto che come fina per gli individui che rispondono cala la libido e crescono i capelli mentre negli altri non fa un bel niente!

C'e' sempre la fregatura sotto!

Ne ho la provo con me stesso quando provai androcur ed etinilestradiolo, capelli ricrebbero tutti pero' castita' completa ero solo da guardare e non toccare tanto non cambiava niente!

Per me hanno scoperto l'acqua calda!

[oponzio]

scusa di che cura parli quando ti riferisci a

androcur ed etinilestradiolo?

magari gli effetti collaterali sono soggettivi.

[gavin3]

ti garantisco che gli effetti di questa cura avrebbero su chiunque un effetto terribile!

Ammazza il testosterone e prende piede etinilestradiolo!

[Ronald]

bah nn credo proprio

 

i soggetti che prendevano placebo avevano impotenza al 4%, quindi da imputare a niente. con duta solo 6%, quindi come se fosse 2% alla fin fine

[gavin3]

Ronald allora provala naturalmente parlo della duta e facci sapere!

Se poi vedi che il frugoletto fa le bizze sei sempre in tempo a smettere!

[Ronald]

difatti è quello ke intendo fare, anke se al momento nn è possibile reperirla...

riskio un po' e se vedo ke da buoni risultati e poki effetti collaterali (meglio sarebbe nessuno) ben venga!